| Views | |
|---|---|
| Ustekinumab for the treatment of moderate‐to‐severe plaque psoriasis in paediatric patients (≥ 6 to < 12 years of age): efficacy, safety, pharmacokinetic and biomarker results from the open‐label CADMUS Jr study | 130 |
| March 2025 | April 2025 | May 2025 | June 2025 | July 2025 | August 2025 | September 2025 | |
|---|---|---|---|---|---|---|---|
| Ustekinumab for the treatment of moderate‐to‐severe plaque psoriasis in paediatric patients (≥ 6 to < 12 years of age): efficacy, safety, pharmacokinetic and biomarker results from the open‐label CADMUS Jr study | 2 | 0 | 0 | 5 | 14 | 0 | 0 |
| Views | |
|---|---|
| 2020_Philipp_etal.pdf | 162 |
